Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.
about
Harnessing the immune system to improve cancer therapyProducer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumorsCAR models: next-generation CAR modifications for enhanced T-cell functionNew Strategies for the Treatment of Solid Tumors with CAR-T CellsRole of the tumor microenvironment in mature B-cell lymphoid malignanciesRegulation of IL-10 and IL-12 production and function in macrophages and dendritic cellsChimeric Antigen Receptors Modified T-Cells for Cancer TherapyMesothelin-Targeted CARs: Driving T Cells to Solid TumorsAdoptive T-Cell ImmunotherapyAdoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptorsStrategies for combining immunotherapy with radiation for anticancer therapyChimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall StreetCARs in chronic lymphocytic leukemia -- ready to driveInterleukin 12: still a promising candidate for tumor immunotherapy?Adoptive cell therapy for sarcomaUsing gene therapy to manipulate the immune system in the fight against B-cell leukemiasGenetically modified T cells in cancer therapy: opportunities and challengesImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationRecent Developments in Cellular Immunotherapy for HSCT-Associated ComplicationsCD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic LeukaemiaCAR therapy: the CD19 paradigmT cell engineering as therapy for cancer and HIV: our synthetic futureEnhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case studySmart CARs engineered for cancer immunotherapyDesigning chimeric antigen receptors to effectively and safely target tumorsInduction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective studyClinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemiaFCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical RelevanceBiology and clinical application of CAR T cells for B cell malignanciesThe basic principles of chimeric antigen receptor design.CAR-modified T-cell therapy for cancer: an updated review.Driving CAR T-cells forwardArmed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.Targeting CD8+ T-cell tolerance for cancer immunotherapy.New insights into IL-12-mediated tumor suppression.The Ikaros transcription factor regulates responsiveness to IL-12 and expression of IL-2 receptor alpha in mature, activated CD8 T cells.CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts
P2860
Q26738698-9390131A-2BF3-43FC-8BC4-605132B065DDQ26741260-F00313D9-BDAC-47EE-B7F1-390BA38B307BQ26745600-4F4A1C7A-403D-477A-AE09-46E2E7B51CA2Q26748500-AE4F4403-D6D3-441C-AF00-A4CA6CA9F508Q26748775-8B3F809E-5DFE-44CB-B873-30907386A46AQ26766184-446263F2-E8B1-453C-9FBB-B9E1370E2053Q26773309-4DB5F20A-24EA-402A-A3F6-0EB972F1B8CCQ26778759-6C721095-F2EC-4D7E-87BC-20E3C9E8003AQ26782845-050C922E-6586-414B-94CF-E2142CD519C8Q26795540-2538152A-922E-48C0-A8B6-0DB4168AA7DFQ26796675-FE8AF48F-BAD8-4446-AB64-FC943C3AE625Q26799357-328CF6D2-B738-4421-91B8-5E14C165E51FQ26830526-FDFB029F-3C27-4369-BFDE-64ED76348F25Q26861559-85168823-A8C4-4917-9910-D04048D8285CQ27009541-16AFB942-D7C7-4D8A-9219-9F9099F7E32EQ27011297-DF24516C-0790-4126-BEA3-617410F85002Q27026627-1F8C8C9A-07F6-4002-A9CB-569F5EAB099EQ28068378-AF505716-20D9-4CC9-B418-436BA237CE61Q28079823-FF8D8945-4625-46F1-9E37-A9A94CDBBD60Q28081600-042CBA7E-EF12-4074-88D2-1064C147B351Q28081642-8C76375D-A6B3-4AAE-B38A-B4EB3A1D2C34Q28082253-8230926A-E1C8-4641-8A16-B1FECA6AD918Q28084489-989115A3-8521-4587-8152-8550BC1F2885Q28087236-BD97D0DA-DCF2-48BC-9146-589B5C2CBECFQ28088526-3E90B7CD-37F5-4732-91B7-48C754D3737AQ28538654-48369089-6DF8-453A-992B-32ABE4F061D8Q30542070-C4302532-7783-4FD2-B878-A0648F7EC2FFQ33564364-181DE823-38FE-4EC1-973D-4360356703EFQ33607015-82D8302C-DD5A-4126-AD78-2527DAE923B0Q33907565-93994AC1-54DD-4D7D-A50B-582DF11652BBQ34036213-5D435409-BFAD-4C5B-A3AF-74949B8442CCQ34044213-4608D39C-555F-476F-A6F5-2F07475F47A1Q34046505-D320F67D-84A1-4DC8-98E8-439728B9A419Q34205181-94A187E6-B82A-4BCF-B93B-E9935AFE5643Q34432692-20BEFA1D-7276-4469-AE30-0CC5E0AFFE1AQ34436897-8F36D835-C380-4488-99F8-841F3EA25E06Q34618230-60E81868-4433-47A1-B89E-1DCD0648A9A1Q34667972-B3AAC5D4-62F8-4D14-A09A-D1639FE422F5Q34985536-2FF33AF5-6522-48FB-AE73-D134EDCD7815Q35040517-48F92794-CD71-43A7-94EA-5F0EA8E34694
P2860
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Tumor-targeted T cells modifie ...... t need for prior conditioning.
@ast
Tumor-targeted T cells modifie ...... t need for prior conditioning.
@en
type
label
Tumor-targeted T cells modifie ...... t need for prior conditioning.
@ast
Tumor-targeted T cells modifie ...... t need for prior conditioning.
@en
prefLabel
Tumor-targeted T cells modifie ...... t need for prior conditioning.
@ast
Tumor-targeted T cells modifie ...... t need for prior conditioning.
@en
P2093
P2860
P1433
P1476
Tumor-targeted T cells modifie ...... t need for prior conditioning.
@en
P2093
Erik G Hayman
Gavin H Imperato
Hollie J Pegram
James C Lee
Michel Sadelain
Renier J Brentjens
Thomas F Tedder
P2860
P304
P356
10.1182/BLOOD-2011-12-400044
P407
P577
2012-02-21T00:00:00Z